Medidata Solutions (MDSO) Rating Lowered to C+ at TheStreet

Medidata Solutions (NASDAQ:MDSO) was downgraded by equities research analysts at TheStreet from a “b” rating to a “c+” rating in a research report issued on Thursday.

MDSO has been the topic of several other reports. SunTrust Banks reissued a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Jefferies Group reissued a “hold” rating and issued a $78.00 target price on shares of Medidata Solutions in a research report on Tuesday, August 22nd. Deutsche Bank assumed coverage on Medidata Solutions in a research report on Friday, December 8th. They issued a “buy” rating and a $78.00 target price on the stock. Zacks Investment Research raised Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Friday, November 10th. Finally, Dougherty & Co assumed coverage on Medidata Solutions in a research report on Thursday, November 2nd. They issued a “neutral” rating on the stock. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.54.

Shares of Medidata Solutions (MDSO) traded up $2.28 on Thursday, hitting $66.64. The stock had a trading volume of 1,058,215 shares, compared to its average volume of 456,868. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. Medidata Solutions has a 12-month low of $47.77 and a 12-month high of $85.92. The stock has a market cap of $3,762.55, a price-to-earnings ratio of 77.54, a PEG ratio of 3.99 and a beta of 1.69.

Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The firm had revenue of $140.08 million for the quarter, compared to the consensus estimate of $141.27 million. During the same period in the prior year, the firm earned $0.28 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. research analysts forecast that Medidata Solutions will post 0.78 earnings per share for the current fiscal year.

In other Medidata Solutions news, CEO Tarek Sherif sold 200,000 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Carlos Dominguez sold 9,066 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the sale, the director now directly owns 66,020 shares in the company, valued at $4,413,437. The disclosure for this sale can be found here. Insiders have sold a total of 237,010 shares of company stock worth $16,305,136 over the last ninety days. 5.80% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Alps Advisors Inc. grew its position in Medidata Solutions by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 8,430 shares of the company’s stock worth $659,000 after purchasing an additional 22 shares during the period. 1st Global Advisors Inc. grew its position in Medidata Solutions by 0.5% during the 2nd quarter. 1st Global Advisors Inc. now owns 8,243 shares of the company’s stock worth $645,000 after purchasing an additional 37 shares during the period. State Board of Administration of Florida Retirement System grew its position in shares of Medidata Solutions by 0.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 33,828 shares of the company’s stock valued at $2,645,000 after acquiring an additional 109 shares during the period. Pinebridge Investments L.P. grew its position in shares of Medidata Solutions by 2.1% during the 2nd quarter. Pinebridge Investments L.P. now owns 7,305 shares of the company’s stock valued at $572,000 after acquiring an additional 153 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Medidata Solutions by 10.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after acquiring an additional 208 shares during the period. 97.52% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Medidata Solutions (MDSO) Rating Lowered to C+ at TheStreet” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2017/12/16/medidata-solutions-mdso-rating-lowered-to-c-at-thestreet.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply